Courtagen is a privately held life sciences and molecular information company based in Woburn, Massachusetts that converts genomic data into actionable clinical information for diagnosis of critical pediatric neurological and metabolic disorders. The company sells proprietary genomic diagnostic and drug metabolism assays focused on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders. Its Next Generation Sequencing clinical laboratory integrates genotype, phenotype, and disease mechanism data using cloud-based computing and custom analytical methods to provide comprehensive results for clinicians, patients, and families. Courtagen recently completed a financing that adds approximately $20 million of new growth equity to its balance sheet. The company intends to use the proceeds to expand its ability to deliver services while maintaining strong financial and operating discipline. Courtagen aims to build into a world-class, global enterprise with greater capabilities, reach, and impact to help physicians treat patients.

Total raised

$20M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2015